Saptak Chem & Business has notified BSE Limited of a Board of Directors meeting scheduled for Thursday, May 14, 2026, at its registered office located at the 6th Floor, B-Wing, B D Patel House, Naranpura, Ahmedabad. The intimation has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Agenda

The board meeting has been convened to consider and approve key financial and compliance matters for the concluded fiscal year. The following items are on the agenda:

• Audited financial results for the quarter and financial year ended March 31, 2026, along with the Auditor's Report and Certificate for unmodified opinion, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Any other business with the permission of the Chairman

Meeting Details

The key details of the scheduled board meeting are as follows:

The intimation was submitted on May 08, 2026, and was signed by Jubin Premji Gada, Director of the company.

Saptak Chem & Business Limited has announced a significant equity acquisition through preferential allotment, with Jayshree Jain emerging as a substantial shareholder. The transaction, disclosed under SEBI's substantial acquisition regulations on April 8, 2026, marks a notable expansion in the company's equity base and investor participation.

Acquisition Details

The acquisition involves Jayshree Jain, who does not belong to the promoter or promoter group, acquiring shares through preferential allotment. The transaction was completed on April 6, 2026, with formal disclosure made under Regulation 29(1) of SEBI (SAST) Regulations, 2011.

Shareholding Impact

The acquisition represents a substantial stake in the company, with Jayshree Jain securing a significant voting position. Prior to this transaction, the acquirer held no shares in the company.

Capital Structure Changes

The preferential allotment has resulted in a substantial expansion of the company's equity base. The transaction involves convertible warrants, with each warrant convertible into one fully paid equity share of ₹10.00 each.

Regulatory Compliance

The disclosure has been made in accordance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company's shares are listed on BSE Limited, ensuring transparency and regulatory oversight of the transaction.

The convertible nature of the securities provides flexibility for future equity conversion, with the warrants carrying specific terms for conversion into fully paid equity shares. This structure allows for potential future expansion of the acquirer's stake based on the conversion timeline and terms specified in the warrant agreement.